2Seventy Bio Inc

2Seventy Bio — Corporate Update (November 2024)

22 slides from 2Seventy Bio's corporate update, Nov 12, 2024

  1. Slide 1: Unleash Time: 2seventy bio company presentation

    Unleash Time 2seventy bio company presentation November 2024

  2. Slide 2: Cautionary note regarding forward-looking statements

    2 Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development an

  3. Slide 3: Unlocking Abecma Value in 2024

    Unlocking Abecma Value in 2024 3 Abecma opportunity to see sustainable growth Strong cash and path to profitability Lean, fit-for-purpose structure • First-in-class CAR T treatment for 3L+ r/r multiple myeloma • $358M total US commercial revenue in 2023; $183M Q3 2024 YTD • ~7 months into the launch

  4. Slide 4: Strategic realignment successfully executed in 1H 2024

    Strategic realignment successfully executed in 1H 2024: sale of R&D assets to Regeneron and Novo Nordisk 4 Completed sale of R&D business to Regeneron in April 2024: sold oncology and autoimmune research and development programs 2seventy focused exclusively on development and commercialization of Ab

  5. Slide 5: KarMMa-3 supports the totality of Abecma's competitive profile

    5 KarMMa-3 supports the totality of Abecma’s competitive profile in a population of patients with high unmet need Abecma is now available for the treatment of adult patients with relapsed or refractory multiple myeloma earlier in their treatment journey SUPERIOR EFFICACY VS. STANDARD REGIMENS 3x lon

  6. Slide 6: Abecma real world experience shows consistent outcomes with KarMMa

    • Several large global studies show Abecma efficacy in the real world is consistent or better than the KarMMa study • Many RWE patients across all studies would not have met the eligibility criteria for KarMMa • Safety data similar to KarMMa with no new safety signals; limited Parkinsonism and Guill

  7. Slide 7: KarMMa-3 has potential to drive label expansion into broad U.S. market

    KarMMa-3 study has the potential to drive label expansion into broad U.S. market opportunity 7 Addressable U.S. Patients on Abecma label over time M ul tip le M ye lo m a 0 5,000 10,000 15,000 20,000 25,000 2021 2024 2028+ ~4,000 ~12,000 ~5,000 KarMMa: initial approval in 2021 based off study in lat

  8. Slide 8: Key questions on Abecma in earlier lines

    Key questions on Abecma in earlier lines 8 What did we learn from KarMMa-3 in terms of OS? What does this mean for Abecma in the 3L+ commercial setting? What are you doing to shift the dynamics in the market? What other evidence generation strategies are you pursuing? • KarMMa-2 cohort 2c data demon

  9. Slide 9: KarMMa-3

    KarMMa-3 9Rodríguez-Otero P, et al. ASH 2023 Abstract 1028

  10. Slide 10: KarMMa-3 study design (NCT03651128)

    KarMMa-3 study design (NCT03651128) 10 ➤ KarMMa-3 updated analysis R 2:1 Key inclusion criteria • 2-4 previous regimens (including an IMiD agent, PI, and daratumumab) • Refractory to the last regimen Stratification factors • Age (< 65 vs ≥ 65 years) • Number of previous regimens (2 vs 3 or 4) • High

  11. Slide 11: Heavily Pretreated, Triple Class Exposed Patient Population

    Heavily Pretreated, Triple Class Exposed* Patient Population 11 ➤ KarMMa-3 updated analysis Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 Characteristic Ide-cel (n = 254) Standard regimens (n = 132) Median (range) age, years 63 (30–81) 63 (42–83) Median (range) time from diagnosis to screening, y

  12. Slide 12: Significant benefit with ide-cel at final PFS analysis

    Significant benefit with ide-cel at final PFS analysis (ITT population) 12Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-

  13. Slide 13: Statistically significant, deep and durable responses with ide-cel

    10 26 18 11 41 5 0 20 40 60 80 100 Ide-cel Standard regimens Statistically significant, deep and durable responses with ide-cel Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis Per IMWG criteria. Individual responses may not sum to ORR due to rounding. aOR is for ORR, cal

  14. Slide 14: OS analysis confounded by substantial crossover

    Information fraction for OS was 74% (n = 164/222 required events). aBased on Kaplan–Meier approach; bStratified HR is based on the univariate Cox proportional hazards model. CI is 2-sided and calculated by bootstrap method; cTwo-stage Weibull model without recensoring (prespecified analysis). NR, no

  15. Slide 15: Patients who never received ide-cel drive imbalance in early OS events

    Patients who never received ide-cel drive imbalance in early OS events 15Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 aAll 4 cases of “death from other cause” in the ide-cel arm were reported verbatim as ”unknown”, which was coded under the system organ class of “general disorder and administrat

  16. Slide 16: Suboptimal bridging therapy

    Suboptimal bridging therapy 16 Cumulative dose during bridging therapy for the ide-cel arm and cycles 1 and 2 for the standard regimens arm was defined as the sum of all doses taken in mg. Dose intensity was defined as the cumulative dose divided by total days. aFor patients in the ide-cel arm, brid

  17. Slide 17: Trend of OS benefit with ide-cel among treated patients

    Trend of OS benefit with ide-cel among treated patients 17Rodríguez-Otero P, et al. ASH 2023 Abstract 1028 ➤ KarMMa-3 updated analysis aBased on Kaplan–Meier approach; bStratified HR based on the univariate Cox proportional hazards model. CI is two-sided. O S (% ) HR 0.83 (95% CI, 0.58–1.18) Median

  18. Slide 18: KarMMa-3 Data Supports the Potential of Abecma in 3L+

    KarMMa-3 Data Supports the Potential of Abecma in 3L+ 18 • KarMMa-3 demonstrates a significantly longer and clinically meaningful improvement of PFS with ide-cel versus standard regimens in patients with early line relapse and triple-class exposed* (TCExp) RRMM across all subgroups1 – 51% reduction

  19. Slide 19: KarMMa-2c and KarMMa-9

    KarMMa-2c and KarMMa-9 eseventybio/

  20. Slide 20: Update on KarMMa-9 Study

    Update on KarMMa-9 Study 20 The initiation of KarMMa-9 in a NDMM population was based on the positive data generated in KarMMa-2 cohort 2c in a similar patient population. Since that time, NDMM treatment landscape has improved considerably: • Increasing use of quadruplet therapy induction • Incorpor

  21. Slide 21: KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT

    KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT (less than VGPR) 21 The bar starts at month 2, day 1 (equivalent to 1 month post ide-cel infusion) and continues to later of last response assessment date or data cutoff date (May 3, 2023). Response was defined as ≥

  22. Slide 22: Thank You

    THANK YOU eseventybio/

2seventy bio — Corporate Update (November 2024) on 6ix